Companies / Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc.

Nasdaq: ACXPCIK 1736243STATEN ISLAND, NY

Financials

Revenue—
Net income$-7.97M
Total debt—
Cash$14.46M
Diluted EPS$-5.32
Shares outstanding4.3M

Ownership

4.3M shares outstanding · as of May 11, 2026
3.5%Institutions
Ownership
Institutions3.51%151,011
Public float96.49%4,146,727

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Deluccia Robert JDirector
——
Harrison Thomas LDirector
——
Luci David PCEOPresident and CEO · Director
——
Scodari Joseph CDirector
——

Institutional holders 18

View all →
HolderValue% of shares
Millennium Management LLC$103.2K0.96%
Geode Capital Management, LLC$92.1K0.58%
Vanguard Group Inc$58.0K0.54%
Prospect Financial Services LLC$49.4K0.46%
Northern Trust Corp$42.1K0.39%
Jane Street Group, LLC$26.8K0.25%
Morgan Stanley$16.2K0.15%
Tower Research Capital LLC (TRC)$7.2K0.07%
Wells Fargo & COMPANY/MN$5.7K0.05%
Nbc Securities, Inc.$3.7K0.03%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Apr 20, 2026Scodari Joseph C
Director
GrantStock Option—+2K
2,150
0.05% of shares
low
Apr 20, 2026Luci David P
CEO
GrantStock Option—+37K
37,100
0.86% of shares
low
Apr 20, 2026Harrison Thomas L
Director
GrantStock Option—+2K
2,150
0.05% of shares
low
Apr 20, 2026Deluccia Robert J
Director
GrantStock Option—+37K
37,100
0.86% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
ACXPCommon StockEquity00510M203BBG01184DNJ4